Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide

• US 20080318837A1
• Filed: 12/01/2006
• Published: 12/25/2008
• Est. Priority Date: 12/26/2003
• Status: Abandoned Application

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Nastech Pharmaceutical Company Inc. (Adhera Therapeutics, Inc.)
• Inventors: Quay, Steven C., Costantino, Henry R., Templin, Michael V., Kleppe, Mary S., Leonard, Alexis Kays, Sestak, Joshua O.
• Application Number:
  US12/095,801
• Publication Number:
  US 20080318837A1
• Time in Patent Office: Days
• US Class Current: 514/2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/18 Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 47/40 Cyclodextrins; Derivatives thereof
• CPC Class Codes: A61K 9/0043 Nose

Abstract

What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.

Claims

1-42. -42. (canceled)

43. An aqueous pharmaceutical formulation for intranasal delivery comprising a therapeutically effective amount of exendin-4 or an exendin-4 agonist analog, a permeation-enhancing solubilizing agent, a permeation-enhancing cation chelator, a buffer and optionally a permeation-enhancing viscosity enhancing agent, wherein

a. the solubilizing agent is selected from at least one of the group consisting of hydroxypropyl-β

-cyclodextrin, sulfobutylether-β

-cyclodextrin, dimethyl-β

-cyclodextrin, methyl-β

-cyclodextrin and Cremophor EL, and

b. the viscosity enhancer is selected from at least one of the group consisting of gelatin, methylcellulose and hydroxypropylmethylcellulose, and wherein

c. the formulation provides at least 5% permeation of exendin-4 in an in vitro tissue permeation assay, has a viscosity up to 150 cps, has a pH from 2 to 8 and is stable at least two weeks at 5°

C.

44. The formulation of claim 43, wherein the solubilizing agent is methyl-β

-cyclodextrin.

45. The formulation of claim 44, wherein methyl-β

-cyclodextrin is present at a concentration of up to 90 mg/ml.

46. The formulation of claim 45, wherein methyl-β

-cyclodextrin is present at 80 mg/ml.

47. The formulation of claim 43, wherein the chelator is selected from at least one of the group consisting of ethylene diamine tetraacetic acid and ethylene glycol tetraacetic acid.

48. The formulation of claim 47, wherein the chelator is present at a concentration of up to 10 mg/ml.

49. The formulation of claim 48, wherein the chelator is present at 5 mg/ml.

50. The formulation of claim 43, wherein the solubilizing agent concentration is 80 mg/ml and the chelator concentration is 5 mg/ml.

51. The formulation of claim 43, wherein the buffer is a mono-ionogenic buffer.

52. The formulation of claim 51, wherein the mono-ionogenic buffer is selected from at least one of the group consisting of acetate, arginine and lactate.

53. The formulation of claim 52, wherein the mono-ionogenic buffer is arginine.

54. The formulation of claim 53, wherein arginine is present at a concentration greater than or equal to 2.8 mM.

55. The formulation of claim 43, wherein the pH is from 4.7 to 5.5.

56. The formulation of claim 43, wherein a preservative is not present.

57. The formulation of claim 43, wherein the viscosity is from 1.5 to 10.0 cps.

58. The formulation of claim 43, wherein the formulation is stable for at least 4 weeks at 5°

C.

59. A method of treating a subject in need or desirous thereof, comprising administering the aqueous pharmaceutical formulation of claim 43 to the subject by intranasal delivery to treat a metabolic disease selected from the group consisting of hyperglycemia, insulin dependent diabetes mellitus, gestational diabetes, non insulin-dependent diabetes mellitus, obesity or dyslipidemia or to treat a condition benefited by suppressing appetite, increasing satiety, promoting weight loss, decreasing food intake, slowing gastric emptying, lowering plasma glucose or promoting insulin secretion.